AirInSpace to extend international market expansion
An estimated €6m ($8.5m) is being put behind the international market expansion of an airborne anti-microbial technology.
It is designed to protect patients and hospital staff from airborne biological pathogens and nosocomial infections and stems from plasma-based air treatment technology.
The new round of finance will be key in fuelling the company’s growth in the US, Asia and Europe. It will also bring in additional industry experience to the company’s board of directors, said company chief executive officer Laurent Fullana.
“We are now in a position to ramp up international sales and support more hospitals all over the world with new technology that ensures safe air for better health,” he said.
The €6m series ‘B’ round of financing was led by Matignon Technologies II FCPR, with Oddo AM (through FCPI Générations Futures) as a second investor. Aelios Finance served as financial advisor for the company.
Working with several world-renowned laboratories, AirInSpace has shown that its plasma-based air treatment technology eliminates a wide range of microorganisms, including: Vaccinia virus (smallpox surrogate), Avian flu virus (H5N2), Aspergillus niger, Staphylococcus aureus, toxic shock syndrome, meningitis, endocarditis and pneumonia, and Serratia marcescens – an agent of urinary tract and wound infections.
AirInSpace’s flagship product is a mobile air-decontamination unit called Plasmair. The Plasmair’s performance has been clinically proven to lower airborne biological loads and is now being used to combat nosocomial infection to protect patients, staff and products in high-risk areas of more than 100 hospitals and clinics throughout France, including haematology wards, ICUs, pharmacies and operating theatres.